AONCW / American Oncology Network, Inc. - Equity Warrant - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-04321 American Oncology Network, Inc. (Exact nam

Executive Compensation Clawback Policy

AMERICAN ONCOLOGY NETWORK, INC. CLAWBACK POLICY Introduction The Board of Directors of the Company (the "Board") believes that it is in the best interests of the Company and its shareholders to provide for the recovery of erroneously awarded incentive-based compensation received by current or former executive officers, create and maintain a culture that emphasizes integrity and accountability and

Stockholders Agreement (incorporated by reference to Exhibit 10.3 of the Company’s Quarterly Report on Form 10-Q filed November 13, 2024).).

Exhibit 10.3 STOCKHOLDERS AGREEMENT between AMERICAN ONCOLOGY NETWORK, INC. and AEA GROWTH MANAGEMENT LP Dated as of July 18, 2024 USACTIVE\126982270\V-6 TABLE OF CONTENTS Section VI.1 Additional AEA Parties. 9 i USACTIVE\126982270\V-6 304084503 v6 STOCKHOLDERS AGREEMENT STOCKHOLDERS AGREEMENT (this “Agreement”), dated as of July 18, 2024 between American Oncology Network, Inc., a Delaware corpora

Description of Securities

Exhibit 4.5 DESCRIPTION OF SECURITIES Capital Stock The following summary of the material terms of the securities of AON. This summary is not intended to be a complete summary of the rights and preferences of such securities. We urge you to read our Charter in its entirety for a complete description of the rights and preferences of our securities. Authorized and Outstanding Stock Our charter autho

David Afshar Employment and Severance Benefits Agreement, dated June 1, 2024 (incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q filed August 14, 2024).

EMPLOYMENT AND SEVERANCE BENEFITS AGREEMENT THIS EMPLOYMENT AND SEVERANCE BENEFITS AGREEMENT (the “Agreement”) is made and entered into effective as of the “Commencement Date” (as hereinafter defined) by and between AON Central Services, LLC, a Delaware limited liability company (the “Company”), and David Afshar (the “Employee”).

Amendment No. 1 to the Amended and Restated Registration Rights Agreement (incorporated by reference to Exhibit 10.2 of the Company’s Quarterly Report on Form 10-Q filed November 13, 2024).).

AMENDMENT NO. 1 TO AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT This AMENDMENT NO. 1 TO AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this “Amendment”) is dated as of November 12, 2024, by and among American Oncology Network, Inc., a Delaware corporation (the “Company”), AEA Growth Equity Fund LP and AEA Growth Equity Fund (Parallel) LP (collectively, “AEA Growth”), AEA AON Purchaser L

Class A Common Stock Purchase Agreement, dated November 12, 2024 (incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q filed November 13, 2024).).

CLASS A COMMON STOCK PURCHASE AGREEMENT This CLASS A COMMON STOCK PURCHASE AGREEMENT (collectively, with all Exhibits hereto, this “Agreement”) is entered into as of November 12, 2024 (the “Effective Date”), by and between AEA AON Aggregator LLC (the “Buyer”) and American Oncology Network, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 333-274975 American Oncology Network, Inc. (Exact name of registrant as spec

Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 1, 2024 American Oncology Network, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of

Central Georgia Cancer Care, P.C. Financial Statements As of and for the Year Ended December 31, 2023

EX-99.1 2 ef20040705ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Central Georgia Cancer Care, P.C. Financial Statements As of and for the Year Ended December 31, 2023 Page(s) Report of Independent Auditors 1-2 Financial Statements Balance Sheet 3 Statement of Operations 4 Statement of Shareholders’ Equity 5 Statement of Cash Flows 6 Notes to Financial Statements 7 389 Mulberry Street | Macon, Georgia 3120

Central Georgia Cancer Care, P.C. Financial Statements As of and for the Year Ended December 31, 2023

Central Georgia Cancer Care, P.C. Financial Statements As of and for the Year Ended December 31, 2023 Page(s) Report of Independent Auditors................................................... 1-2 Financial Statements Balance Sheet......................................................................................3 Statement of Operations...........................................................

Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 American Oncology Network, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of incorporatio

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On April 1, 2024, consolidated subsidiaries of American Oncology Network, Inc.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2024 American Oncology Network, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of incorpor

As filed with the Securities and Exchange Commission on December 11, 2024 Registration No. 333-275757 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENTS UNDER THE

As filed with the Securities and Exchange Commission on December 11, 2024 Registration No.

As filed with the Securities and Exchange Commission on December 11, 2024

As filed with the Securities and Exchange Commission on December 11, 2024 Registration No.

AMERICAN ONCOLOGY NETWORK, INC. Primary Offering of 8,337,500 Shares of Class A Common Stock Secondary Offering of 51,161,832 Shares of Class A Common Stock 6,113,333 Warrants to Purchase Shares of Class A Common Stock

Filed Pursuant to Rule 424(b)(3) Registration No. 333-274975 Prospectus Supplement No. 6 AMERICAN ONCOLOGY NETWORK, INC. Primary Offering of 8,337,500 Shares of Class A Common Stock Secondary Offering of 51,161,832 Shares of Class A Common Stock 6,113,333 Warrants to Purchase Shares of Class A Common Stock This prospectus supplement is being filed to update and supplement the information contained

Stockholders Agreement between the Company and AEA Growth

Exhibit 10.3 STOCKHOLDERS AGREEMENT between AMERICAN ONCOLOGY NETWORK, INC. and AEA GROWTH MANAGEMENT LP Dated as of July 18, 2024 USACTIVE\126982270\V-6 TABLE OF CONTENTS Section VI.1 Additional AEA Parties. 9 i USACTIVE\126982270\V-6 304084503 v6 STOCKHOLDERS AGREEMENT STOCKHOLDERS AGREEMENT (this “Agreement”), dated as of July 18, 2024 between American Oncology Network, Inc., a Delaware corpora

Amendment No. 1 to Registration Rights Agreement

AMENDMENT NO. 1 TO AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT This AMENDMENT NO. 1 TO AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this “Amendment”) is dated as of November 12, 2024, by and among American Oncology Network, Inc., a Delaware corporation (the “Company”), AEA Growth Equity Fund LP and AEA Growth Equity Fund (Parallel) LP (collectively, “AEA Growth”), AEA AON Purchaser L

Class A Common Stock Purchase Agreement

CLASS A COMMON STOCK PURCHASE AGREEMENT This CLASS A COMMON STOCK PURCHASE AGREEMENT (collectively, with all Exhibits hereto, this “Agreement”) is entered into as of November 12, 2024 (the “Effective Date”), by and between AEA AON Aggregator LLC (the “Buyer”) and American Oncology Network, Inc.

Stockholders Agreement between the Company and AEA Growth

Exhibit 10.3 STOCKHOLDERS AGREEMENT between AMERICAN ONCOLOGY NETWORK, INC. and AEA GROWTH MANAGEMENT LP Dated as of July 18, 2024 USACTIVE\126982270\V-6 TABLE OF CONTENTS Section VI.1 Additional AEA Parties. 9 i USACTIVE\126982270\V-6 304084503 v6 STOCKHOLDERS AGREEMENT STOCKHOLDERS AGREEMENT (this “Agreement”), dated as of July 18, 2024 between American Oncology Network, Inc., a Delaware corpora

Amendment No. 1 to Registration Rights Agreement

AMENDMENT NO. 1 TO AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT This AMENDMENT NO. 1 TO AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this “Amendment”) is dated as of November 12, 2024, by and among American Oncology Network, Inc., a Delaware corporation (the “Company”), AEA Growth Equity Fund LP and AEA Growth Equity Fund (Parallel) LP (collectively, “AEA Growth”), AEA AON Purchaser L

Class A Common Stock Purchase Agreement

CLASS A COMMON STOCK PURCHASE AGREEMENT This CLASS A COMMON STOCK PURCHASE AGREEMENT (collectively, with all Exhibits hereto, this “Agreement”) is entered into as of November 12, 2024 (the “Effective Date”), by and between AEA AON Aggregator LLC (the “Buyer”) and American Oncology Network, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-04177 American Oncology Network, Inc. (

AMERICAN ONCOLOGY NETWORK, INC. Primary Offering of 8,337,500 Shares of Class A Common Stock Secondary Offering of 51,161,832 Shares of Class A Common Stock 6,113,333 Warrants to Purchase Shares of Class A Common Stock

Filed Pursuant to Rule 424(b)(3) Registration No. 333-274975 Prospectus Supplement No. 5 AMERICAN ONCOLOGY NETWORK, INC. Primary Offering of 8,337,500 Shares of Class A Common Stock Secondary Offering of 51,161,832 Shares of Class A Common Stock 6,113,333 Warrants to Purchase Shares of Class A Common Stock This prospectus supplement is being filed to update and supplement the information contained

Employment and Severance Benefits Agreement between the Company and David Afshar

EMPLOYMENT AND SEVERANCE BENEFITS AGREEMENT THIS EMPLOYMENT AND SEVERANCE BENEFITS AGREEMENT (the “Agreement”) is made and entered into effective as of the “Commencement Date” (as hereinafter defined) by and between AON Central Services, LLC, a Delaware limited liability company (the “Company”), and David Afshar (the “Employee”).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-04177 American Oncology Network, Inc. (Exact

Employment and Severance Benefits Agreement between the Company and David Afshar

employmentandseverancebe EMPLOYMENT AND SEVERANCE BENEFITS AGREEMENT THIS EMPLOYMENT AND SEVERANCE BENEFITS AGREEMENT (the “Agreement”) is made and entered into effective as of the “Commencement Date” (as hereinafter defined) by and between AON Central Services, LLC, a Delaware limited liability company (the “Company”), and David Afshar (the “Employee”).

AMERICAN ONCOLOGY NETWORK, INC. Primary Offering of 8,337,500 Shares of Class A Common Stock Secondary Offering of 51,161,832 Shares of Class A Common Stock 6,113,333 Warrants to Purchase Shares of Class A Common Stock

Filed Pursuant to Rule 424(b)(3) Registration No. 333-274975 Prospectus Supplement No. 4 AMERICAN ONCOLOGY NETWORK, INC. Primary Offering of 8,337,500 Shares of Class A Common Stock Secondary Offering of 51,161,832 Shares of Class A Common Stock 6,113,333 Warrants to Purchase Shares of Class A Common Stock This prospectus supplement is being filed to update and supplement the information contained

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2024 American On

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2024 American Oncology Network, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of incorporatio

AMERICAN ONCOLOGY NETWORK, INC. Primary Offering of 8,337,500 Shares of Class A Common Stock Secondary Offering of 51,161,832 Shares of Class A Common Stock 6,113,333 Warrants to Purchase Shares of Class A Common Stock

Filed Pursuant to Rule 424(b)(3) Registration No. 333-274975 Prospectus Supplement No. 3 AMERICAN ONCOLOGY NETWORK, INC. Primary Offering of 8,337,500 Shares of Class A Common Stock Secondary Offering of 51,161,832 Shares of Class A Common Stock 6,113,333 Warrants to Purchase Shares of Class A Common Stock This prospectus supplement is being filed to update and supplement the information contained

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 American Oncology Network, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of incorporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-40177 American Oncology N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-40177 American Oncology Network, Inc. The Nasdaq Stock Market LLC (Exact name of Issuer as specified in its charter and name of Exchange where security is listed and/or regist

American Oncology Network Announces Voluntary Delisting From Nasdaq

American Oncology Network Announces Voluntary Delisting From Nasdaq FORT MYERS, Fla.

AMERICAN ONCOLOGY NETWORK, INC. Primary Offering of 8,337,500 Shares of Class A Common Stock Secondary Offering of 51,161,832 Shares of Class A Common Stock 6,113,333 Warrants to Purchase Shares of Class A Common Stock

Filed Pursuant to Rule 424(b)(3) Registration No. 333-274975 Prospectus Supplement No. 2 AMERICAN ONCOLOGY NETWORK, INC. Primary Offering of 8,337,500 Shares of Class A Common Stock Secondary Offering of 51,161,832 Shares of Class A Common Stock 6,113,333 Warrants to Purchase Shares of Class A Common Stock This prospectus supplement is being filed to update and supplement the information contained

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2024 American Oncology Network, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of incorporation

AMERICAN ONCOLOGY NETWORK, INC. Primary Offering of 8,337,500 Shares of Class A Common Stock Secondary Offering of 51,161,832 Shares of Class A Common Stock 6,113,333 Warrants to Purchase Shares of Class A Common Stock

Filed Pursuant to Rule 424(b)(3) Registration No. 333-274975 Prospectus Supplement No. 1 AMERICAN ONCOLOGY NETWORK, INC. Primary Offering of 8,337,500 Shares of Class A Common Stock Secondary Offering of 51,161,832 Shares of Class A Common Stock 6,113,333 Warrants to Purchase Shares of Class A Common Stock This prospectus supplement is being filed to update and supplement the information contained

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-04321 American Oncology Network, Inc. (Exac

American Oncology Network, Inc. Announces First Quarter 2024 Financial Results

Exhibit 99.1 American Oncology Network, Inc. Announces First Quarter 2024 Financial Results First Quarter 2024 Highlights •Revenue of $364.3 million increased by 20.0% compared to the prior year quarter oPatient encounter growth of 7.1% as compared to the prior year quarter •Added 17 new providers to the AON platform oExpanded in Texas and Maryland markets FORT MYERS, Fla., May 15, 2024 – American

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 American Oncology Network, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of incorporation

AMERICAN ONCOLOGY NETWORK, INC. Primary Offering of 8,337,500 Shares of Class A Common Stock Secondary Offering of 51,161,832 Shares of Class A Common Stock 6,113,333 Warrants to Purchase Shares of Class A Common Stock

TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No.333-274975 PROSPECTUS AMERICAN ONCOLOGY NETWORK, INC. Primary Offering of 8,337,500 Shares of Class A Common Stock Secondary Offering of 51,161,832 Shares of Class A Common Stock 6,113,333 Warrants to Purchase Shares of Class A Common Stock This prospectus relates to (i) the issuance by us of up to 8,337,500 shares of class A commo

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2024 American Oncology Network, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of incorporati

As filed with the Securities and Exchange Commission on April 29, 2024

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on April 29, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A AMENDMENT NO. 1

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A AMENDMENT NO. 1 x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-04321 American Oncology Networ

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2024 American Oncology Network, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of incorporati

MiBA: A New Era in Data-Driven Oncology Insights for a Healthier Tomorrow The innovative healthcare technology startup utilizes data analytics to improve cancer care.

Contact for more information: Partnerships Team Meaningful Insights Biotech Analytics partnerships@mibanalytics.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 American Oncology Network, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of incorporatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-04321 American Oncology Network, Inc. (Exact nam

American Oncology Network, Inc. (“AON”) Announces Fourth Quarter and Full Year 2023 Financial Results

Exhibit 99.1 American Oncology Network, Inc. (“AON”) Announces Fourth Quarter and Full Year 2023 Financial Results •Fiscal Year 2023 Revenue was $1,279.2 million, an 11.3% increase over 2022 oPatient encounter growth of 7.9% as compared to the prior fiscal year •Fourth Quarter 2023 Revenue was $324.2 million, a 7.9% increase over 2022 oPatient encounter growth of 9.5% as compared to the prior year

Description of Securities

Exhibit 4.5 DESCRIPTION OF SECURITIES Capital Stock The following summary of the material terms of the securities of AON. This summary is not intended to be a complete summary of the rights and preferences of such securities. We urge you to read our Charter in its entirety for a complete description of the rights and preferences of our securities. Authorized and Outstanding Stock Our charter autho

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 American Oncology Network, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of incorporati

Executive Compensation Clawback Policy

AMERICAN ONCOLOGY NETWORK, INC. CLAWBACK POLICY Introduction The Board of Directors of the Company (the "Board") believes that it is in the best interests of the Company and its shareholders to provide for the recovery of erroneously awarded incentive-based compensation received by current or former executive officers, create and maintain a culture that emphasizes integrity and accountability and

AMERICAN ONCOLOGY NETWORK, INC. Primary Offering of 8,337,500 Shares of Class A Common Stock Secondary Offering of 51,161,832 Shares of Class A Common Stock 6,113,333 Warrants to Purchase Shares of Class A Common Stock

TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No. 333-274975 PROSPECTUS AMERICAN ONCOLOGY NETWORK, INC. Primary Offering of 8,337,500 Shares of Class A Common Stock   Secondary Offering of 51,161,832 Shares of Class A Common Stock 6,113,333 Warrants to Purchase Shares of Class A Common Stock This prospectus relates to (i) the issuance by us of up to 8,337,500 shares of class A co

AMERICAN ONCOLOGY NETWORK, INC. 14543 Global Parkway, Suite 110 Fort Myers, FL 33913 Telephone: (833) 886-1725

AMERICAN ONCOLOGY NETWORK, INC. 14543 Global Parkway, Suite 110 Fort Myers, FL 33913 Telephone: (833) 886-1725 December 4, 2023 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, DC 20549-3010 Attn: Nicholas O’ Leary Re: American Oncology Network, Inc. Registration Statement on For

Calculation of Filing Fee Tables FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AMERICAN ONCOLOGY NETWORK, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Tables FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AMERICAN ONCOLOGY NETWORK, INC.

Three Months Ended September 30,

Exhibit 99.2 AON MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis provides information which AON’s management believes is relevant to an assessment and understanding of AON’s results of operations and financial condition. You should read the following discussion and analysis of AON’s financial condition and results of opera

As filed with the Securities and Exchange Commission on November 27, 2023

As filed with the Securities and Exchange Commission on November 27, 2023 Registration No.

Financial Statements and Exhibits, Other Events

false000183999800018399982023-11-272023-11-270001839998aonc:WarrantsEachWholeWarrantExercisableForOneShareOfClassACommonStockMember2023-11-272023-11-270001839998us-gaap:CommonClassAMember2023-11-272023-11-27 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

INDEX TO FINANCIAL STATEMENTS INDEX TO CONSOLIDATED FINANCIAL INFORMATION

Exhibit 99.1 INDEX TO FINANCIAL STATEMENTS   INDEX TO CONSOLIDATED FINANCIAL INFORMATION Page Consolidated Financial Statements of American Oncology Network, Inc. Report of Independent Registered Public Accounting Firm F-2 Consolidated Balance Sheets as of December 31, 2022 and 2021 F-3 Consolidated Statements of Operations and Comprehensive Income (Loss) for the years ended December 31, 2022, 202

As filed with the Securities and Exchange Commission on November 17, 2023

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 17, 2023 Registration No.

* * *

Brian Lee Partner [email protected] D +1 212 768 6926 Dentons US LLP 1221 Avenue of the Americas New York, NY 10020-1089 United States dentons.com Brian Lee Partner November 17, 2023 United States Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, DC 20549-3010 Re: American Oncology Network, Inc. Regi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-04321 American Oncology Network, Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 America

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 American Oncology Network, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of incorpor

American Oncology Network, Inc. Announces Third Quarter 2023 Financial Results

Exhibit 99.1 American Oncology Network, Inc. Announces Third Quarter 2023 Financial Results Third Quarter 2023 Highlights •Revenue of $336.3 million increased by 13.1% compared to the prior year quarter. •Successfully transitioned to a publicly traded company with the completion of our business combination with Digital Transformation Opportunities Corp. •Expanded into Florida market with Florida O

Joint Filing Agreement, dated November 9, 2023, by and among the Reporting Persons (filed herewith).

EX-1 2 tm2330181d1ex1.htm EXHIBIT 1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that

DTOC / Digital Transformation Opportunities Corp - Class A / HealthQuest Tactical Opportunities Fund, L.P. - SC 13D Activist Investment

SC 13D 1 tm2330181d1sc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. )* American Oncology Network, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securit

Filing Fee Tables FORM S-1 (Form Type) AMERICAN ONCOLOGY NETWORK, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Filing Fee Tables FORM S-1 (Form Type) AMERICAN ONCOLOGY NETWORK, INC.

As filed with the Securities and Exchange Commission on October 13, 2023

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on October 13, 2023 Registration No.

Form of Class B Warrant

Exhibit 4.2 Final Form THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS AND HAS BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNEC-TION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT OR QUALIFICATION RELATE

Form of Indemnification Agreement

Exhibit 99.1 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of , 2023 between American Oncology Network, Inc., a Delaware corporation (the “Company”), and [Name] (“Indemnitee”). WITNESSETH THAT: WHEREAS, highly competent persons have become more reluctant to serve corporations as directors or in other capacities unless they are provided with

DTOC / Digital Transformation Opportunities Corp - Class A / AEA GROWTH EQUITY FUND LP - SC 13D/A Activist Investment

SC 13D/A 1 d456650dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* American Oncology Network, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securities) 028719102 (CUSIP Number) Michelle Marcellus AEA Growth Management LP One Letterman Dr

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2023 American Oncology Network, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of incorporat

Stock Purchase Agreement, dated October 9, 2023, by and among AEA Growth Equity Fund LP, AEA Growth Equity Fund (Parallel) LP, and HealthQuest Tactical Opportunities Fund, L.P. (filed as Exhibit 99.D of AEA Growth Equity Fund LP’s Schedule 13D Amendment No.1 as filed with the Commission on October 13, 2023 and incorporated herein by reference).

EX-99.D 2 d456650dex99d.htm EX-99.D Exhibit 99.D STOCK PURCHASE AGREEMENT This Stock Transfer Agreement (this “Agreement”) is made and entered into by and among AEA Growth Equity Fund LP, AEA Growth Equity Fund (Parallel) LP (each a “Transferor” and collectively, the “Transferors”) and HealthQuest Tactical Opportunities Fund, L.P. (“Transferee”) effective as of the first date on which each of the

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

EX-99.E 3 d456650dex99e.htm EX-99.E Exhibit 99.E October 12, 2023 American Oncology Network, Inc. 14543 Global Parkway, Suite 110 Fort Myers, FL 33913 Ladies and Gentlemen: In addition to any shares of Class A Common Stock, par value $0.0001 per share (the “Class A Common Stock”), of American Oncology Network, Inc. (the “Company”) the undersigned may hold, the undersigned holds shares of Series A

DTOC / Digital Transformation Opportunities Corp - Class A / Digital Transformation Sponsor LLC - SC 13D Activist Investment

UNITED STATES SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* American Oncology Network, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securities) 028719102 (CUSIP Number) Digital Transformation Sponsor LLC 10250 Constellation Blvd., Suite 2316 Los Angeles, CA 90067 (360) 9

Joint Filing Agreement dated October 2, 2023

EX-99.3 2 tm2327239d2ex3.htm EXHIBIT 3 Exhibit 3 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D may be filed on behalf of each of the undersigned without the necessity of filing additional joint filin

Power of Attorney for Brian R. Hoesterey.

EX-99.B EXHIBIT B POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Barbara L. Burns signing individually, the undersigned’s true and lawful attorney-in fact and agent to: (i) prepare execute and file, for and on behalf of the undersigned, any and all documents and filings that are required or advisable to be made with the United States Securities a

Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.

EX-99.A EXHIBIT A JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned acknowledge and agree that the Statement on Schedule 13D filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Class A common stock, par value $0.0001 per share, of

DTOC / Digital Transformation Opportunities Corp - Class A / AEA GROWTH EQUITY FUND LP - SC 13D Activist Investment

SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* American Oncology Network, Inc. (Name of Issuer) Class A common stock, $0.0001 par value per share (Title of Class of Securities) 028719102 (CUSIP Number) Michelle Marcellus AEA Growth Management LP One Letterman Drive Building C, Suite CM200 San F

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2023 American Oncology Network, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of incorpo

Delivering Better Care Together Investor Presentation September 2023 General This presentation is for use by prospective supporters and investors in American Oncology Network, Inc. (the “Company”) as described herein. The presentation was created for

Delivering Better Care Together Investor Presentation September 2023 General This presentation is for use by prospective supporters and investors in American Oncology Network, Inc.

Subsidiaries of New AON.

Exhibit 21.1 Subsidiaries of the Registrant Name of Subsidiary Jurisdiction of Incorporation or Organization American Oncology Network, LLC Delaware American Oncology Management Company, LLC Delaware American Oncology Partners, P.A. Florida American Oncology Partners of Maryland, P.A. Maryland AON Receivables, LLC Delaware AON Receivables Maryland, LLC Maryland AON Central Services, LLC Delaware A

Letter from Marcum dated September 26, 2023.

Exhibit 16.1 September 26, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by American Oncology Network, Inc. (formerly Digital Transformation Opportunities Corp.) under Item 4.01 of its Form 8-K dated September 20, 2023. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agr

Certificate of Designations of Series A Preferred Stock of American Oncology Network, Inc.

Exhibit 3.4 CERTIFICATE OF DESIGNATIONS OF SERIES A PREFERRED STOCK OF AMERICAN ONCOLOGY NETWORK, INC. Pursuant to Section 151 of the General Corporation Law of the State of Delaware AMERICAN ONCOLOGY NETWORK, INC., a Delaware corporation, certifies that pursuant to the authority contained in Article Fourth of its Certificate of Incorporation, and in accordance with the provisions of Section 151 o

American Oncology Network and Digital Transformation Opportunities Corp. Announce Completion of Business Combination AON to Ring Nasdaq’s Closing Bell on September 21, 2023, to Commemorate First Day of Trading

Exhibit 99.1 American Oncology Network and Digital Transformation Opportunities Corp. Announce Completion of Business Combination AON to Ring Nasdaq’s Closing Bell on September 21, 2023, to Commemorate First Day of Trading FORT MYERS, Fla. and LOS ANGELES – September 20, 2023 – American Oncology Network, LLC (“AON” or the “Company”), a rapidly growing network of community-based oncology practices,

Amended and Restated Bylaws of New AON.

  Exhibit 3.3   AMENDED AND RESTATED BYLAWS OF AMERICAN ONCOLOGY NETWORK, INC.   (adopted on September 20, 2023)   Article I   OFFICES   Section 1.1.      Registered Office. The registered office of American Oncology Network, Inc. (the “Corporation”) shall be fixed in the Corporation’s certificate of incorporation, as the same may be amended from time to time.   Section 1.2.      Additional Office

Second Amended & Restated Certificate of Incorporation.

Exhibit 3.2 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF Digital Transformation Opportunities Corp. September 20, 2023 Digital Transformation Opportunities Corp., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY AS FOLLOWS: 1. The name of the Corporation is “Digital Transformation Opportunities Corp.” The original

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Introduction Digital Transformation Opportunities Corp., a Delaware corporation (“DTOC”) and American Oncology Network, LLC, a Delaware limited liability company (the “Company” or “AON”) are providing the following unaudited pro forma condensed combined financial information to aid you in your analysis of the financial aspec

American Oncology Network, LLC Fourth Amended and Restated Limited Liability Company Agreement

Exhibit 3.1 Execution Copy [Certain information has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as amended, because it is both (i) not material and (ii) the type of information that the Registrant treats as confidential. The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.] AMERICAN ONCOLOGY

Amended and Restated Registration Rights Agreement by and among the Issuer, the Sponsor and the other signatories thereto (incorporated by reference to Exhibit 10.2 to the Issuer’s Current Report on Form 8-K filed on September 26, 2023).

Exhibit 10.2 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT This Amended And Restated Registration Rights Agreement (this “Agreement” as amended, restated, supplemented, or otherwise modified from time to time) dated as of September 20, 2023, is made and entered into by and among American Oncology Network, Inc. (formerly known as Digital Transformation Opportunities Corp.), a Delaware corporat

Regulation FD Disclosure, Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendment to Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Change in Shell Company Status, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant, Completion of Acquisition or Disposition of Assets, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 20, 2023 American Oncology Network, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of incorporation)

New AON 2023 Incentive Equity Plan

Exhibit 10.4 AMERICAN ONCOLOGY NETWORK, INC. 2023 INCENTIVE EQUITY PLAN 1. Purposes of the Plan; Award Types. (a) Purposes of the Plan. The purposes of this Plan are to attract and retain personnel for positions with the Company Group, to provide additional incentive to Employees, Directors, and Consultants (collectively, “Service Providers”), and to promote the success of the Company’s business.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2023 Digita

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2023 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2023 Digita

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2023 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 15, 2023 Digital Transf

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 15, 2023 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of inco

AON MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Exhibit 99.2 AON MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis provides information which AON’s management believes is relevant to an assessment and understanding of AON’s results of operations and financial condition. You should read the following discussion and analysis of AON’s financial condition and results of opera

The accompanying notes are an integral part of these condensed consolidated financial statements.

Exhibit 99.1 American Oncology Network, LLC Condensed Consolidated Balance Sheets (Unaudited) ($ in thousands, except share data) As of June 30, 2023 As of December 31, 2022 Assets Current assets Cash and cash equivalents $ 72,708 $ 26,926 Short-term marketable securities 9,984 9,851 Patient accounts receivable, net 145,159 136,098 Inventories 41,886 36,476 Other receivables 32,929 28,201 Prepaids

The accompanying notes are an integral part of these condensed consolidated financial statements.

Exhibit 99.1 American Oncology Network, LLC Condensed Consolidated Balance Sheets (Unaudited) ($ in thousands, except share data) As of June 30, 2023 As of December 31, 2022 Assets Current assets Cash and cash equivalents $ 72,708 $ 26,926 Short-term marketable securities 9,984 9,851 Patient accounts receivable, net 145,159 136,098 Inventories 41,886 36,476 Other receivables 32,929 28,201 Prepaids

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 15, 2023 Digital Transf

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 15, 2023 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of inco

AON MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Exhibit 99.2 AON MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis provides information which AON’s management believes is relevant to an assessment and understanding of AON’s results of operations and financial condition. You should read the following discussion and analysis of AON’s financial condition and results of opera

SUPPLEMENTAL PROXY STATEMENT FOR SPECIAL MEETING STOCKHOLDERS OF DIGITAL TRANSFORMATION OPPORTUNITIES CORP. PROSPECTUS SUPPLEMENT September 15, 2023 PROSPECTUS SUPPLEMENT FOR UP TO 1,236,480 SHARES OF CLASS A COMMON STOCK OF AMERICAN ONCOLOGY NETWORK

Filed Pursuant to Rule 424(b)(3) Registration No. 333-271482 Prospectus Supplement (to Proxy/Prospectus dated July 18, 2023) SUPPLEMENTAL PROXY STATEMENT FOR SPECIAL MEETING STOCKHOLDERS OF DIGITAL TRANSFORMATION OPPORTUNITIES CORP. PROSPECTUS SUPPLEMENT September 15, 2023 PROSPECTUS SUPPLEMENT FOR UP TO 1,236,480 SHARES OF CLASS A COMMON STOCK OF AMERICAN ONCOLOGY NETWORK, INC. (f/k/a DIGITAL TRA

Promissory Note dated as of August 21, 2023.

Exhibit 10.1 THIS PROMISSORY NOTE (THIS “NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COM

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2023 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2023 Digital T

425 1 tm2324279d18k.htm 425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2023 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (St

Promissory Note dated as of August 21, 2023.

Exhibit 10.1 THIS PROMISSORY NOTE (THIS “NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2023 Digital T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2023 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2023 Digital T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2023 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to DIGITAL TRANSFORMATION OPP

Promissory Note dated as of July 24, 2023.

Exhibit 10.1 THIS PROMISSORY NOTE (THIS “NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 Digital Tra

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of i

Promissory Note dated as of July 24, 2023.

Exhibit 10.1 THIS PROMISSORY NOTE (THIS “NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 Digital Tra

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of i

PROXY STATEMENT FOR SPECIAL MEETING OF STOCKHOLDERS OF DIGITAL TRANSFORMATION OPPORTUNITIES CORP. (A DELAWARE CORPORATION) PROSPECTUS FOR UP TO 1,236,480 SHARES OF CLASS A COMMON STOCK OF AMERICAN ONCOLOGY NETWORK, INC. (f/k/a DIGITAL TRANSFORMATION

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(3)  Registration No. 333-271482 PROXY STATEMENT FOR SPECIAL MEETING OF STOCKHOLDERS OF DIGITAL TRANSFORMATION OPPORTUNITIES CORP. (A DELAWARE CORPORATION) PROSPECTUS FOR UP TO 1,236,480 SHARES OF CLASS A COMMON STOCK OF AMERICAN ONCOLOGY NETWORK, INC. (f/k/a DIGITAL TRANSFORMATION OPPORTUNITIES CORP. UPON CONSUMMATION OF THE BUSINESS COMBINATION AS

Master Services Agreement Between American Oncology Management Company, LLC and American Oncology Partners of Maryland, P.A., dated January 1, 2020 (incorporated by reference to Exhibit 10.14 of the Company’s Registration Statement on Form S-4/A filed July 14, 2023).

Exhibit 10.14 Pursuant to Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as amended, certain exhibits have been omitted because they are both (i) not material and (ii) the type of information that the Registrant treats as confidential. The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request. MANAGEMENT SERVICES AGREEMENT TH

As filed with the Securities and Exchange Commission on July 14, 2023

As filed with the Securities and Exchange Commission on July 14, 2023 Registration No.

Digital Transformation Opportunities Corp. 10250 Constellation Blvd, Suite 23126 Los Angeles, CA 90067

Digital Transformation Opportunities Corp. 10250 Constellation Blvd, Suite 23126 Los Angeles, CA 90067 July 14, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Jane Park Ms. Loan Lauren Nguyen Re: Digital Transformation Opportunities Corp. Amendment No. 4 t

Master Services Agreement Between American Oncology Management Company, LLC and American Oncology Partners, P.A., dated July 1, 2018 (incorporated by reference to Exhibit 10.13 of the Company’s Registration Statement on Form S-4/A filed July 14, 2023).

Exhibit 10.13 Pursuant to Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as amended, certain exhibits have been omitted because they are both (i) not material and (ii) the type of information that the Registrant treats as confidential. The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request. MANAGEMENT SERVICES AGREEMENT TH

Second Amended and Restated Business Combination Agreement, dated as of April 27, 2023, by and among Digital Transformation Opportunities Corp. and American Oncology Network, LLC

Exhibit 2.3 Execution Copy SECOND AMENDED AND RESTATED BUSINESS COMBINATION AGREEMENT by and between DIGITAL TRANSFORMATION OPPORTUNITIES CORP. and AMERICAN ONCOLOGY NETWORK, LLC Dated as of April 27, 2023 1 TABLE OF CONTENTS Page ARTICLE I CERTAIN DEFINITIONS 6 Section 1.01 Definitions 6 Section 1.02 Construction 19 Section 1.03 Equitable Adjustments 20 ARTICLE II TRANSACTIONS 20 Section 2.01 Clo

First Amended and Restated Business Combination Agreement, dated as of January 6, 2023, by and among Digital Transformation Opportunities Corp. and American Oncology Network, LLC

  Exhibit 2.2 Execution Copy AMENDED AND RESTATED BUSINESS COMBINATION AGREEMENT by and between DIGITAL TRANSFORMATION OPPORTUNITIES CORP. and American Oncology Network, LLC Dated as of January 6, 2023 TABLE OF CONTENTS Page Article I CERTAIN DEFINITIONS 2 Section 1.01 Definitions 2 Section 1.02 Construction 18 Section 1.03 Equitable Adjustments 19 Article II TRANSACTIONS 19 Section 2.01 Closing T

Third Amended and Restated Business Combination Agreement, dated as of June 7, 2023, by and among Digital Transformation Opportunities Corp. and American Oncology Network, LLC

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 12, 2023 Registration No.

Master Services Agreement Between American Oncology Management Company, LLC and American Oncology Partners of Maryland, P.A., dated January 1, 2020

Exhibit 10.14 Pursuant to Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as amended, certain exhibits have been omitted because they are both (i) not material and (ii) the type of information that the Registrant treats as confidential. The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request. MANAGEMENT SERVICES AGREEMENT TH

Master Services Agreement Between American Oncology Management Company, LLC and American Oncology Partners, P.A., dated July 1, 2018

Exhibit 10.13 Pursuant to Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as amended, certain exhibits have been omitted because they are both (i) not material and (ii) the type of information that the Registrant treats as confidential. The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request. MANAGEMENT SERVICES AGREEMENT TH

Business Combination Agreement, dated as of October 5, 2022, by and among Digital Transformation Opportunities Corp. and American Oncology Network, LLC

Exhibit 2.1 Execution Version BUSINESS COMBINATION AGREEMENT by and between DIGITAL TRANSFORMATION OPPORTUNITIES CORP. and American Oncology Network, LLC Dated as of October 5, 2022 TABLE OF CONTENTS Page Article I CERTAIN DEFINITIONS 2 Section 1.01 Definitions 2 Section 1.02 Construction 18 Section 1.03 Equitable Adjustments 18 Article II TRANSACTIONS 19 Section 2.01 Closing Transactions 19 Secti

* * *

July 12, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Jeanne Bennett Mr. Brian Cascio Ms. Jane Park Ms. Loan Lauren Nguyen Re: Digital Transformation Opportunities Corp. Amendment No. 2 to Registration Statement on Form S-4 Filed June 29, 2023 File No. 3

Business Combination Agreement, dated as of October 5, 2022, by and among Digital Transformation Opportunities Corp. and American Oncology Network, LLC

Exhibit 2.1 Execution Version Pursuant to Item 601(b)(2)(ii) and Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as amended, the Disclosure Schedules to this exhibit have been omitted because they are both (i) not material and (ii) the type of information that the Registrant treats as confidential. The Registrant agrees to furnish a copy of all omitted exhibits and schedule

Second Amended and Restated Business Combination Agreement, dated as of April 27, 2023, by and among Digital Transformation Opportunities Corp. and American Oncology Network, LLC

Exhibit 2.3 Execution Copy Pursuant to Item 601(b)(2)(ii) and Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as amended, the Disclosure Schedules to this exhibit have been omitted because they are both (i) not material and (ii) the type of information that the Registrant treats as confidential. The Registrant agrees to furnish a copy of all omitted exhibits and schedules t

First Amended and Restated Business Combination Agreement, dated as of January 6, 2023, by and among Digital Transformation Opportunities Corp. and American Oncology Network, LLC

  Exhibit 2.2 Execution Copy Pursuant to Item 601(b)(2)(ii) and Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as amended, the Disclosure Schedules to this exhibit have been omitted because they are both (i) not material and (ii) the type of information that the Registrant treats as confidential. The Registrant agrees to furnish a copy of all omitted exhibits and schedules

As filed with the Securities and Exchange Commission on June 28, 2023

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 28, 2023 Registration No.

Master Services Agreement Between American Oncology Management Company, LLC and American Oncology Partners of Maryland, P.A., dated January 1, 2020

Exhibit 10.14 Pursuant to Item 601(b)(2)(ii) and Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as amended, certain exhibits have been omitted because they are both (i) not material and (ii) the type of information that the Registrant treats as confidential. The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request. MANAGEMEN

Master Services Agreement Between American Oncology Management Company, LLC and American Oncology Partners, P.A., dated July 1, 2018

Exhibit 10.13 Pursuant to Item 601(b)(2)(ii) and Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as amended, certain exhibits have been omitted because they are both (i) not material and (ii) the type of information that the Registrant treats as confidential. The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request. MANAGEMEN

* * *

June 28, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Jeanne Bennett Mr. Brian Cascio Ms. Jane Park Ms. Loan Lauren Nguyen Re: Digital Transformation Opportunities Corp. Amendment No. 1 to Registration Statement on Form S-4 Filed June 15, 2023 File No. 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2023 Digital Tra

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2023 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of i

Promissory Note dated as of June 26, 2023.

Exhibit 10.1 THIS PROMISSORY NOTE (THIS “NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2023 Digital Tra

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2023 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of i

Promissory Note dated as of June 26, 2023.

Exhibit 10.1 THIS PROMISSORY NOTE (THIS “NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 Digital Tra

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of i

Third Amended and Restated Business Combination Agreement, dated as of June 14, 2023, by and between Digital Transformation Opportunities Corp., American Oncology Network, LLC, GEF AON Holdings Corp. and DTOC Merger Sub, Inc.

Exhibit 2.1 STRICTLY CONFIDENTIAL THIRD AMENDED AND RESTATED BUSINESS COMBINATION AGREEMENT by and among DIGITAL TRANSFORMATION OPPORTUNITIES CORP., American Oncology Network, LLC, GEF AON Holdings Corp. and DTOC MERGER SUB, INC. Dated as of June 14, 2023 TABLE OF CONTENTS Page Article I CERTAIN DEFINITIONS 3 Section 1.01 Definitions 3 Section 1.02 Construction 19 Section 1.03 Equitable Adjustment

Third Amended and Restated Business Combination Agreement, dated as of June 14, 2023, by and between Digital Transformation Opportunities Corp., American Oncology Network, LLC, GEF AON Holdings Corp. and DTOC Merger Sub, Inc.

Exhibit 2.1 STRICTLY CONFIDENTIAL THIRD AMENDED AND RESTATED BUSINESS COMBINATION AGREEMENT by and among DIGITAL TRANSFORMATION OPPORTUNITIES CORP., American Oncology Network, LLC, GEF AON Holdings Corp. and DTOC MERGER SUB, INC. Dated as of June 14, 2023 TABLE OF CONTENTS Page Article I CERTAIN DEFINITIONS 3 Section 1.01 Definitions 3 Section 1.02 Construction 19 Section 1.03 Equitable Adjustment

Consent of Ravi Sarin

EX-99.11 11 dtocu-20230331xex99d11.htm EXHIBIT-99.11 Exhibit 99.11 Consent to be Named as a Director Nominee In connection with the filing by Digital Transformation Opportunities Corp. of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act

Master Services Agreement Between American Oncology Management Company, LLC and American Oncology Partners, P.A., dated July 1, 2018

Exhibit 10.13 MANAGEMENT SERVICES AGREEMENT THIS MANAGEMENT SERVICES AGREEMENT (the “Agreement”) is entered into and effective as of this 1st day of July, 2018 (the “Effective Date”), by and between AMERICAN ONCOLOGY MANAGEMENT COMPANY, LLC, a Delaware limited liability company (“Manager”), and AMERICAN ONCOLOGY PARTNERS, P.A., a Florida professional service corporation (the “Practice”). RECITALS

Master Services Agreement Between American Oncology Management Company, LLC and American Oncology Partners of Maryland, P.A., dated January 1, 2020

EX-10.14 5 dtocu-20230331xex10d14.htm EXHIBIT-10.14 Exhibit 10.14 MANAGEMENT SERVICES AGREEMENT THIS MANAGEMENT SERVICES AGREEMENT (the “Agreement”) is entered into and effective as of this 1st day of January, 2020 (the “Effective Date”), by and between AMERICAN ONCOLOGY MANAGEMENT COMPANY, LLC, a Delaware limited liability company (“Manager”), and AMERICAN ONCOLOGY PARTNERS OF MARYLAND, P.A., a M

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of i

Consent of James Stith

EX-99.10 10 dtocu-20230331xex99d10.htm EXHIBIT-99.10 Exhibit 99.10 Consent to be Named as a Director Nominee In connection with the filing by Digital Transformation Opportunities Corp. of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act

Amended and Restated Sponsor Support Agreement, dated as of January 6, 2023, by and among Digital Transformation Opportunities Corp., Digital Transformation Sponsor LLC, American Oncology Network, LLC and certain equityholders of Digital Transformation Opportunities Corp.

Table of Contents As filed with the Securities and Exchange Commission on June 14, 2023 Registration No.

Amended and Restated Class C Convertible Preferred Unit Purchase Agreement, dated as of June 7, 2023, by and between American Oncology Network, LLC and GEF AON Holdings Corp.

Exhibit 10.15 Execution Version AMENDED AND RESTATED CLASS C CONVERTIBLE PREFERRED UNIT PURCHASE AGREEMENT by and between American Oncology Network, LLC (the “Company”) and GEF AON Holdings Corp. (the “Buyer”), Dated as of June 7, 2023 TABLE OF CONTENTS ARTICLE I – DEFINITIONS 1 1.1 Definitions 1 ARTICLE II – TRANSACTIONS AT THE CLOSING 10 2.1 Purchase and Sale 10 2.2 Closing 10 2.3 Actions of the

Consent of Bradley Fluegel

EX-99.9 9 dtocu-20230331xex99d9.htm EXHIBIT-99.9 Exhibit 99.9 Consent to be Named as a Director Nominee In connection with the filing by Digital Transformation Opportunities Corp. of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to

* * *

June 14, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Jeanne Bennett Mr. Brian Cascio Ms. Jane Park Ms. Loan Lauren Nguyen Re: Digital Transformation Opportunities Corp. Registration Statement on Form S-4 Filed April 28, 2023 File No. 333-271482 Ladies a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 Digital Tran

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 Digital Tran

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to DIGITAL TRANSFORMATION OP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 Digital Trans

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of inc

Promissory Note dated May 1, 2023

Exhibit 10.1 THIS PROMISSORY NOTE (THIS “NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COM

Promissory Note dated May 1, 2023

Exhibit 10.1 THIS PROMISSORY NOTE (THIS “NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 Digital Trans

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2023 Digital Tr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2023 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2023 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of

###

Exhibit 99.1 American Oncology Network, a Rapidly Growing Network of Community-Based Oncology Practices, Receives Strategic Investment from AEA Growth. FORT MYERS, Fla., April 28, 2023 (GLOBE NEWSWIRE) - American Oncology Network (“AON” or the “Company”), a rapidly growing network of community-based oncology practices, today announced that the Company has entered into a definitive agreement to rec

###

Exhibit 99.1 American Oncology Network, a Rapidly Growing Network of Community-Based Oncology Practices, Receives Strategic Investment from AEA Growth. FORT MYERS, Fla., April 28, 2023 (GLOBE NEWSWIRE) - American Oncology Network (“AON” or the “Company”), a rapidly growing network of community-based oncology practices, today announced that the Company has entered into a definitive agreement to rec

Proposed Footnote Disclosure to Revised YTD 9/30/22 Unaudited Financial Statements

Exhibit 99.1 Proposed Footnote Disclosure to Revised YTD 9/30/22 Unaudited Financial Statements Subsequent to the original issuance of the condensed consolidated interim financial statements as of and for the nine-month period ended September 30, 2022, AON identified certain misstatements. · AON incorrectly accounted for marketable securities, which were considered to be available-for-sale, acquir

Consent of Douglas Heldreth, MD

Exhibit 99.6 CONSENT TO REFERENCE IN PROXY STATEMENT/PROSPECTUS April 26, 2023 Digital Transformation Opportunities Corp. (to be renamed American Oncology Network Inc.) 10250 Constellation Blvd, Suite 23126 Los Angeles, California 90067 Digital Transformation Opportunities Corp. (the “Company”) is filing a Registration Statement on Form S-4 with the Securities and Exchange Commission under the Sec

Consent of Vipul Patel, MD

Exhibit 99.7 CONSENT TO REFERENCE IN PROXY STATEMENT/PROSPECTUS April 26, 2023 Digital Transformation Opportunities Corp. (to be renamed American Oncology Network Inc.) 10250 Constellation Blvd, Suite 23126 Los Angeles, California 90067 Digital Transformation Opportunities Corp. (the “Company”) is filing a Registration Statement on Form S-4 with the Securities and Exchange Commission under the Sec

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-4 Digital Transformation Opportunities Corp.

As filed with the Securities and Exchange Commission on April 27, 2023

Table of Contents As filed with the Securities and Exchange Commission on April 27, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 Digital Tr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of

Consent of Stephen “Fred” Divers, MD

Exhibit 99.4 CONSENT TO REFERENCE IN PROXY STATEMENT/PROSPECTUS April 26, 2023 Digital Transformation Opportunities Corp. (to be renamed American Oncology Network Inc.) 10250 Constellation Blvd, Suite 23126 Los Angeles, California 90067 Digital Transformation Opportunities Corp. (the “Company”) is filing a Registration Statement on Form S-4 with the Securities and Exchange Commission under the Sec

Second Amended and Restated Business Combination Agreement, dated as of April 27, 2023, by and between Digital Transformation Opportunities Corp. and American Oncology Network, LLC

Exhibit 2.1 Execution Copy SECOND AMENDED AND RESTATED BUSINESS COMBINATION AGREEMENT by and between DIGITAL TRANSFORMATION OPPORTUNITIES CORP. and AMERICAN ONCOLOGY NETWORK, LLC Dated as of April 27, 2023 1 TABLE OF CONTENTS Page ARTICLE I CERTAIN DEFINITIONS 6 Section 1.01 Definitions 6 Section 1.02 Construction 19 Section 1.03 Equitable Adjustments 20 ARTICLE II TRANSACTIONS 20 Section 2.01 Clo

Consent of Shalin R. Shah, DO

Exhibit 99.5 CONSENT TO REFERENCE IN PROXY STATEMENT/PROSPECTUS April 26, 2023 Digital Transformation Opportunities Corp. (to be renamed American Oncology Network Inc.) 10250 Constellation Blvd, Suite 23126 Los Angeles, California 90067 Digital Transformation Opportunities Corp. (the “Company”) is filing a Registration Statement on Form S-4 with the Securities and Exchange Commission under the Sec

Consent of Vance M. Wright-Browne, MD

Exhibit 99.8 CONSENT TO REFERENCE IN PROXY STATEMENT/PROSPECTUS April 26, 2023 Digital Transformation Opportunities Corp. (to be renamed American Oncology Network Inc.) 10250 Constellation Blvd, Suite 23126 Los Angeles, California 90067 Digital Transformation Opportunities Corp. (the “Company”) is filing a Registration Statement on Form S-4 with the Securities and Exchange Commission under the Sec

Consent of Todd Schonherz

Exhibit 99.3 CONSENT TO REFERENCE IN PROXY STATEMENT/PROSPECTUS April 26, 2023 Digital Transformation Opportunities Corp. (to be renamed American Oncology Network Inc.) 10250 Constellation Blvd, Suite 23126 Los Angeles, California 90067 Digital Transformation Opportunities Corp. (the “Company”) is filing a Registration Statement on Form S-4 with the Securities and Exchange Commission under the Sec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 Digital Tr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of

Proposed Footnote Disclosure to Revised YTD 9/30/22 Unaudited Financial Statements

Exhibit 99.1 Proposed Footnote Disclosure to Revised YTD 9/30/22 Unaudited Financial Statements Subsequent to the original issuance of the condensed consolidated interim financial statements as of and for the nine-month period ended September 30, 2022, AON identified certain misstatements. · AON incorrectly accounted for marketable securities, which were considered to be available-for-sale, acquir

Second Amended and Restated Business Combination Agreement, dated as of April 27, 2023, by and among Digital Transformation Opportunities Corp. and American Oncology Network, LLC

Exhibit 2.1 Execution Copy SECOND AMENDED AND RESTATED BUSINESS COMBINATION AGREEMENT by and between DIGITAL TRANSFORMATION OPPORTUNITIES CORP. and AMERICAN ONCOLOGY NETWORK, LLC Dated as of April 27, 2023 1 TABLE OF CONTENTS Page ARTICLE I CERTAIN DEFINITIONS 6 Section 1.01 Definitions 6 Section 1.02 Construction 19 Section 1.03 Equitable Adjustments 20 ARTICLE II TRANSACTIONS 20 Section 2.01 Clo

*****

April 27, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Jeanne Bennett Mr. Brian Cascio Ms. Jane Park Ms. Loan Lauren Nguyen Re: Digital Transformation Opportunities Corp. Preliminary Proxy Statement on Schedule 14A Filed January 6, 2023 File No. 001-4017

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2023 Digital Tr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2023 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40177

Description of Registrant’s Securities.

Exhibit 4.5 DESCRIPTION OF SECURITIES The following descriptions of securities of Digital Transformation Opportunities Corp. (the “company,” “DTOC,” “we” or “us”) is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to the company’s amended and restated certificate of incorporation and the company’s warrant agreement with Continental Stock T

Amendment to the Investment Management Trust Agreement dated as of March 6, 2023

Exhibit 10.1 AMENDMENT NO. 1 TO THE INVESTMENT MANAGEMENT TRUST AGREEMENT This Amendment No. 1 (this “Amendment”), dated as of March 6, 2023, to the Investment Management Trust Agreement (as defined below) is made by and between Digital Transformation Opportunities Corp. (the “Company”) and Continental Stock Transfer & Trust Company, as trustee (“Trustee”). All terms used but not defined herein sh

Certificate of Amendment to Amended and Restated Certificate of Incorporation

Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DIGITAL TRANSFORMATION OPPORTUNITIES CORP. March 2, 2023 Digital Transformation Opportunities Corp., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY AS FOLLOWS: 1. The name of the Corporation is “Digital Transformation Opportunities

Promissory Note, dated as of March 6, 2023

Exhibit 10.2 THIS PROMISSORY NOTE (“NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 DIGITAL TRA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 DIGITAL TRANSFORMATION OPPORTUNITIES CORP. (Exact name of registrant as specified in its charter) Delaware 001-40177 86-3984427 (State or other jurisdiction of i

Amendment to Amended and Restated Certificate of Incorporation of Digital Transformation Opportunities Corp.

EX-3.1 2 tm238907d1ex3-1.htm EXHIBIT 3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DIGITAL TRANSFORMATION OPPORTUNITIES CORP. March 2, 2023 Digital Transformation Opportunities Corp., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY AS FOLLOWS: 1. The name of the Corporation

Promissory Note, dated as of March 6, 2023.

Exhibit 10.2 THIS PROMISSORY NOTE (“NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY

Amendment to Investment Management Trust Account Agreement, dated March 9, 2021, between Continental Transfer & Trust Company and Digital Transformation Opportunities Corp.

Exhibit 10.1 AMENDMENT NO. 1 TO THE INVESTMENT MANAGEMENT TRUST AGREEMENT This Amendment No. 1 (this “Amendment”), dated as of March 6, 2023, to the Investment Management Trust Agreement (as defined below) is made by and between Digital Transformation Opportunities Corp. (the “Company”) and Continental Stock Transfer & Trust Company, as trustee (“Trustee”). All terms used but not defined herein sh

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 DIGITAL TRA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 DIGITAL TRANSFORMATION OPPORTUNITIES CORP. (Exact name of registrant as specified in its charter) Delaware 001-40177 86-3984427 (State or other jurisdiction of i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2023 Digital

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2023 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2023 Digital

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2023 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 Digital

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction

Digital Transformation Opportunities Corp., Class A / GLAZER CAPITAL, LLC Passive Investment

SC 13G/A 1 dtoc20221231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 Digital Transformation Opportunities Corporation (Name of Issuer) Class A common stock, $0.0001 par value per share (Title of Class of Securities) 25401K107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statemen

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definiti

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2023 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2023 Digital

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2023 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction o

Investor Presentation dated February 2023

Exhibit 99.1 Click To Edit Title Delivering Better Care Together Investor Presentation February 2023 1 Click To Edit Title Disclaimer 2 General This presentation is provided for information purposes only and has been prepared to assist interested parties in making their own evaluation with respect to a potential business combination (the “Potential Transaction”) involving Digital Transformation Op

Click To Edit Title Delivering Better Care Together Investor Presentation February 2023 1

Exhibit 99.1 Click To Edit Title Delivering Better Care Together Investor Presentation February 2023 1 Click To Edit Title Disclaimer 2 General This presentation is provided for information purposes only and has been prepared to assist interested parties in making their own evaluation with respect to a potential business combination (the “Potential Transaction”) involving Digital Transformation Op

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1)

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of Commission Only (as permitted by Rule 14a-6

Digital Transformation Opportunities Corp. 10207 Clematis Court Los Angeles, California 90077 February 1, 2023

Digital Transformation Opportunities Corp. 10207 Clematis Court Los Angeles, California 90077 February 1, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attention: Jane Park Loan Lauren Nguyen Re: Digital Transformation Opportunities Corp. Preliminary Proxy on Schedule 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definiti

January 17, 2023

January 17, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Digital Transformation Opportunities Corp. Preliminary Proxy Statement Ladies and Gentlemen: On behalf of our client, Digital Transformation Opportunities Corp. (the “Company”), the Company is filing with the Securities and Exchange Commission a prelimina

Amended and Restated Sponsor Support Agreement, dated as of January 6, 2023, by and among Digital Transformation Opportunities Corp., Digital Transformation Sponsor LLC, American Oncology Network, LLC and certain equityholders of Digital Transformation Opportunities Corp.

Exhibit 10.1 Execution Version AMENDED AND RESTATED SPONSOR SUPPORT AGREEMENT This AMENDED AND RESTATED SPONSOR SUPPORT AGREEMENT (this ?Agreement?), dated as of January 6, 2023, is made by and among Digital Transformation Opportunities Corp., a Delaware corporation (?Acquiror?), Digital Transformation Sponsor LLC, a Delaware limited liability company (?Sponsor?) and the other Persons set forth on

Amended and Restated Sponsor Support Agreement dated as of January 6, 2023 by and among AON, New AON and the Sponsor Supporting Shareholders. (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed January 6, 2023)

EX-10.1 3 tm232330d1ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Execution Version AMENDED AND RESTATED SPONSOR SUPPORT AGREEMENT This AMENDED AND RESTATED SPONSOR SUPPORT AGREEMENT (this “Agreement”), dated as of January 6, 2023, is made by and among Digital Transformation Opportunities Corp., a Delaware corporation (“Acquiror”), Digital Transformation Sponsor LLC, a Delaware limited liability company (“

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 6, 2023 Digital Transform

DEFA14A 1 tm232330d18k.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 6, 2023 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (Sta

You’ve Exceeded the SEC’s Traffic Limit

U.S. Securities and Exchange Commission You’ve Exceeded the SEC’s Traffic Limit Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes. Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

PREM14A 1 tm2233477-1prem14a.htm PREM14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 6, 2023 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of incorpo

January 6, 2023

January 6, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re:           Digital Transformation Opportunities Corp. Preliminary Proxy Statement Ladies and Gentlemen: On behalf of our client, Digital Transformation Opportunities Corp. (the “Company”), the Company is filing with the Securities and Exchange Commission a

First Amended and Restated Business Combination Agreement, dated as of January 6, 2023, by and among Digital Transformation Opportunities Corp. and American Oncology Network, LLC

EX-2.1 2 tm232330d1ex2-1.htm EXHIBIT 2.1   Exhibit 2.1 Execution Copy AMENDED AND RESTATED BUSINESS COMBINATION AGREEMENT by and between DIGITAL TRANSFORMATION OPPORTUNITIES CORP. and American Oncology Network, LLC Dated as of January 6, 2023 TABLE OF CONTENTS Page Article I CERTAIN DEFINITIONS 2 Section 1.01 Definitions 2 Section 1.02 Construction 18 Section 1.03 Equitable Adjustments 19 Article

Amended and Restated Business Combination Agreement, dated as of January 6, 2023, by and between Digital Transformation Opportunities Corp. and American Oncology Network, LLC

EX-2.1 2 tm232330d1ex2-1.htm EXHIBIT 2.1   Exhibit 2.1 Execution Copy AMENDED AND RESTATED BUSINESS COMBINATION AGREEMENT by and between DIGITAL TRANSFORMATION OPPORTUNITIES CORP. and American Oncology Network, LLC Dated as of January 6, 2023 TABLE OF CONTENTS Page Article I CERTAIN DEFINITIONS 2 Section 1.01 Definitions 2 Section 1.02 Construction 18 Section 1.03 Equitable Adjustments 19 Article

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 8, 2022 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of incorp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One)

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEF 14A 1 tm2229858d1def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of Commission Only (as permitted by Rule 1

American Oncology Network, a Rapidly Growing Network of Community-Based Oncology Practices, to go Public through Business Combination with Digital Transformation Opportunities Corp.

Exhibit 99.1 American Oncology Network, a Rapidly Growing Network of Community-Based Oncology Practices, to go Public through Business Combination with Digital Transformation Opportunities Corp. ? American Oncology Network (AON) is a rapidly growing network of community-based oncology practices ? The proposed transaction values the combined company at a pro forma enterprise value of approximately

Investor Presentation October 2022

Exhibit 99.2 Investor Presentation October 2022 2 Disclaimer General This presentation is provided for information purposes only and has been prepared to assist interested parties in making their own evaluation with respect to a potential business combination (the “Potential Transaction”) involving Digital Transformation Opportunities Corp . (“DTOC”) and American Oncology Network, LLC, a Delaware

Business Combination Agreement, dated as of October 5, 2022, by and among Digital Transformation Opportunities Corp. and American Oncology Network, LLC

Exhibit 2.1 Execution Version BUSINESS COMBINATION AGREEMENT by and between DIGITAL TRANSFORMATION OPPORTUNITIES CORP. and American Oncology Network, LLC Dated as of October 5, 2022 TABLE OF CONTENTS Page Article I CERTAIN DEFINITIONS 2 Section 1.01 Definitions 2 Section 1.02 Construction 18 Section 1.03 Equitable Adjustments 18 Article II TRANSACTIONS 19 Section 2.01 Closing Transactions 19 Secti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 5, 2022 Digital Transform

DEFA14A 1 tm2227227d18k.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 5, 2022 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (St

Form of Registration Rights Agreement

Exhibit 10.2 Final Form AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this ?Agreement? as amended, restated, supplemented, or otherwise modified from time to time) dated as of [ ], 2022, is made and entered into by and among American Oncology Network, Inc. (formerly known as Digital Transformation Opportunities Corp.), a Delaware corpor

Joint Investor Presentation dated October 6, 2022

Exhibit 99.2 Investor Presentation October 2022 2 Disclaimer General This presentation is provided for information purposes only and has been prepared to assist interested parties in making their own evaluation with respect to a potential business combination (the ?Potential Transaction?) involving Digital Transformation Opportunities Corp . (?DTOC?) and American Oncology Network, LLC, a Delaware

Joint Press Release dated October 6, 2022

Exhibit 99.1 American Oncology Network, a Rapidly Growing Network of Community-Based Oncology Practices, to go Public through Business Combination with Digital Transformation Opportunities Corp. · American Oncology Network (AON) is a rapidly growing network of community-based oncology practices · The proposed transaction values the combined company at a pro forma enterprise value of approximately

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 5, 2022 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of incorpo

Sponsor Support Agreement, dated as of October 5, 2022, by and among Digital Transformation Opportunities Corp., Digital Transformation Sponsor LLC, American Oncology Network, LLC and certain equityholders of Digital Transformation Opportunities Corp.

EX-10.1 3 tm2227227d1ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Execution Version SPONSOR SUPPORT AGREEMENT This SPONSOR SUPPORT AGREEMENT (this “Agreement”), dated as of October 5, 2022, is made by and among Digital Transformation Opportunities Corp., a Delaware corporation (“Acquiror”), Digital Transformation Sponsor LLC, a Delaware limited liability company (“Sponsor”) and the other Persons set forth

Form of Registration Rights Agreement

Exhibit 10.2 Final Form AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this ?Agreement? as amended, restated, supplemented, or otherwise modified from time to time) dated as of [ ], 2022, is made and entered into by and among American Oncology Network, Inc. (formerly known as Digital Transformation Opportunities Corp.), a Delaware corpor

Business Combination Agreement, dated as of October 5, 2022, by and between Digital Transformation Opportunities Corp. and American Oncology Network, LLC

Exhibit 2.1 Execution Version BUSINESS COMBINATION AGREEMENT by and between DIGITAL TRANSFORMATION OPPORTUNITIES CORP. and American Oncology Network, LLC Dated as of October 5, 2022 TABLE OF CONTENTS Page Article I CERTAIN DEFINITIONS 2 Section 1.01 Definitions 2 Section 1.02 Construction 18 Section 1.03 Equitable Adjustments 18 Article II TRANSACTIONS 19 Section 2.01 Closing Transactions 19 Secti

Sponsor Support Agreement, dated as of October 5, 2022, by and among Digital Transformation Opportunities Corp., Digital Transformation Sponsor LLC, American Oncology Network, LLC and certain equityholders of Digital Transformation Opportunities Corp.

Exhibit 10.1 Execution Version SPONSOR SUPPORT AGREEMENT This SPONSOR SUPPORT AGREEMENT (this ?Agreement?), dated as of October 5, 2022, is made by and among Digital Transformation Opportunities Corp., a Delaware corporation (?Acquiror?), Digital Transformation Sponsor LLC, a Delaware limited liability company (?Sponsor?) and the other Persons set forth on Schedule I hereto (together with Sponsor,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PU

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT P

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

NT 10-Q 1 tm2211977d2nt10q.htm NT 10-Q SEC File Number: 001-40177 CUSIP Number: 25401K107 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form NCSR For Period Ended: March 31, 2022 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨

Description of Registrant’s Securities.

Exhibit 4.5 DESCRIPTION OF SECURITIES The following descriptions of securities of Digital Transformation Opportunities Corp. (the ?company,? ?DTOC,? ?we? or ?us?) is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to the company?s amended and restated certificate of incorporation and the company?s warrant agreement with Continental Stock T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

SEC File Number: 001-40177 CUSIP Number: 25401K107 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Digital Transformation Opportunities Corp., Class A / Digital Transformation Sponsor LLC - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Digital Transformation Opportunities Corp. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 25401K107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appro

JOINT FILING AGREEMENT

EX-99.1 2 tm226324dex1.htm EXHIBIT 1 Exhibit 1 JOINT FILING AGREEMENT This joint filing agreement (this “Agreement”) is made and entered into as of this 14th day of February, 2022, by and between Digital Transformation Sponsor LLC and Kevin Nazemi. The parties to this Agreement hereby acknowledge and agree that the foregoing statement on Schedule 13G in respect of the shares of Class A Common Stoc

Digital Transformation Opportunities Corp., Class A / GLAZER CAPITAL, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Digital Transformation Opportunities Corp. (Name of Issuer) Shares of Class A common stock, included as part of the units (Title of Class of Securities) 25401K107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPO

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2021 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

SEC File Number: 001-38795 CUSIP Number: 776153108 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PU

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

NT 10-Q 1 tm2118731d2nt10q.htm NT 10-Q SEC File Number: 001-38795 CUSIP Number: 776153108 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: June 30, 2021 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ☐ TRANSITION REPORT P

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2021 Digital Transformation Opportunities Corp. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427 (State or other jurisdiction of in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

NT 10-Q 1 tm2113998d2nt10q.htm NT 10-Q SEC File Number: 001-38795 CUSIP Number: 776153108 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form NCSR For Period Ended: March 31, 2021 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨

DIGITAL TRANSFORMATION OPPORTUNITIES CORP. ANNOUNCES THE SEPARATE TRADING OF ITS CLASS A COMMON STOCK AND WARRANTS, COMMENCING ON APRIL 30, 2021

EX-99.1 2 tm2114483d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 DIGITAL TRANSFORMATION OPPORTUNITIES CORP. ANNOUNCES THE SEPARATE TRADING OF ITS CLASS A COMMON STOCK AND WARRANTS, COMMENCING ON APRIL 30, 2021 Bellevue, WA, April 30, 2021 – Digital Transformation Opportunities Corp. (Nasdaq: DTOCU) (the “Company”) today announced that, commencing on April 30, 2021, holders of the units (the “Units”) sold

Financial Statements and Exhibits, Other Events

8-K 1 tm2114483d18k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2021 DIGITAL TRANSFORMATION OPPORTUNITIES CORP. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427

Financial Statements and Exhibits, Other Events

8-K 1 tm219815d18k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2021 DIGITAL TRANSFORMATION OPPORTUNITIES CORP. (Exact name of registrant as specified in its charter) Delaware 001-40177 85-3984427

DIGITAL TRANSFORMATION OPPORTUNITIES CORP.

EX-99.1 2 tm219815d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 DIGITAL TRANSFORMATION OPPORTUNITIES CORP. Page Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of March 12, 2021 F-3 Notes to Financial Statement F-4 F-1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Shareholders and Board of Directors of Digital Transformation Opportunities Corp. Opinion on the

Letter Agreement, dated March 9, 2021, among Digital Transformation Opportunities Corp., Digital Transformation Sponsor LLC and each of the directors and officers of Digital Transformation Opportunities Corp.

U.S. Securities and Exchange Commission You’ve Exceeded the SEC’s Traffic Limit Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes. Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains

Indemnification Agreement, dated March 9, 2021, between Digital Transformation Opportunities Corp. and Jim Moffatt

EX-10.9 13 tm219509d1ex10-9.htm EXHIBIT 10.9 Exhibit 10.9 INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made and entered into as of March 9, 2021, by and between Digital Transformation Opportunities Corp., a Delaware corporation (the “Company”), and Jim Moffatt (“Indemnitee”). WHEREAS, in light of the litigation costs and risks to directors and officers resulting from t

Digital Transformation Opportunities Corp. Announces Pricing of Upsized $300 Million Initial Public Offering

EX-99.1 14 tm219509d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Digital Transformation Opportunities Corp. Announces Pricing of Upsized $300 Million Initial Public Offering Bellevue, Washington, March 9, 2021 — Digital Transformation Opportunities Corp. (the “Company”) today announced the pricing of its upsized initial public offering of 30,000,000 units at a price of $10.00 per unit. The units are expe

Warrant Agreement, dated March 9, 2021, between Continental Stock Transfer & Trust Company and Digital Transformation Opportunities Corp.

U.S. Securities and Exchange Commission You’ve Exceeded the SEC’s Traffic Limit Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes. Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains

Indemnification Agreement, dated March 9, 2021, between Digital Transformation Opportunities Corp. and Kevin Nazemi

Exhibit 10.5 INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?) is made and entered into as of March 9, 2021, by and between Digital Transformation Opportunities Corp., a Delaware corporation (the ?Company?), and Kevin Nazemi (?Indemnitee?). WHEREAS, in light of the litigation costs and risks to directors and officers resulting from their service to companies, and the desire of

Private Placement Warrant Purchase Agreement, dated March 9, 2021, between Digital Transformation Opportunities Corp. and Digital Transformation Sponsor LLC

EX-10.1 5 tm219509d1ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 PRIVATE PLACEMENT WARRANT PURCHASE AGREEMENT THIS PRIVATE PLACEMENT WARRANT PURCHASE AGREEMENT (as it may from time to time be amended, this “Agreement”), dated as of March 9, 2021, is entered into by and among Digital Transformation Opportunities Corp., a Delaware corporation (the “Company”), and Digital Transformation Sponsor LLC, a Delawa

Indemnification Agreement, dated March 9, 2021, between Digital Transformation Opportunities Corp. and Bradley Fluegel

EX-10.7 11 tm219509d1ex10-7.htm EXHIBIT 10.7 Exhibit 10.7 INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made and entered into as of March 9, 2021, by and between Digital Transformation Opportunities Corp., a Delaware corporation (the “Company”), and Bradley Fluegel (“Indemnitee”). WHEREAS, in light of the litigation costs and risks to directors and officers resulting fr